Electrophysiological assays using oocytes that express human ENaC and the use of phenamil to improve the effect of ENaC enhancers in assays using membrane potential reporting dyes

US10215759B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10215759-B2
Application numberUS-201615257517-A
CountryUS
Kind codeB2
Filing dateSep 6, 2016
Priority dateMay 1, 2001
Publication dateFeb 26, 2019
Grant dateFeb 26, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for identifying human ENaC modulators, preferably ENaC enhancers. Compounds that modulate ENaC function in a cell-based ENaC assay are expected to affect salty taste in humans. The assays described herein have advantages over existing cellular expression systems. In the case of mammalian cells, such assays can be run in standard 96 or 384 well culture plates in high-throughput mode with enhanced assay results being achieved by the use of a compound that inhibits ENaC function, preferably an amiloride derivative such as Phenamil. In the case of the inventive oocyte electrophysiological assays (two-electrode voltage-clamp technique), these assays facilitate the identification of compounds which specifically modulate human ENaC. The assays of the invention provide a robust screen useful to detect compounds that facilitate (enhance) or inhibit hENaC function. Compounds that enhance or block human ENaC channel activity should thereby modulate salty taste in humans.

First claim

Opening claim text (preview).

What is claimed: 1. A method of identifying a compound which modulates taste by: (i) contacting a recombinant or isolated mammalian cell or cell population that expresses a functional human Epithelial Sodium Channel (hENaC) comprising a delta subunit which is at least 95% identical to the polypeptide encoded by SEQ ID NO:7 and an alpha and beta subunit which are respectively at least 95% identical to the polypeptides encoded by SEQ ID NO:1 and 2 with at least one compound, (ii) identifying whether the compound modulates the activity of said functional hENaC; and (iii) based on whether the compound modulates activity of said hENaC identifying the compound as one potentially modulating taste. 2. The method of claim 1 which includes testing the identified compound in a taste test. 3. The method of claim 1 wherein the isolated cell or cell population is human. 4. The method of claim 1 wherein the isolated cell or cell population is selected from the group consisting of MDCK, BHK, COS, NIH3T3, Swiss3T3 and CHO cells. 5. The method of claim 1 wherein the isolated cell or cell population transiently expresses the alpha (or delta), beta and gamma hENaC subunits. 6. The method of claim 1 wherein the isolated cell or cell population stably expresses the alpha (or delta), beta and gamma hENaC subunits. 7. The method of claim 1 wherein the isolated cell or cell population are comprised in a multi-well test plate device. 8. The method of claim 1 wherein the isolated cell or cell population are loaded with a membrane potential dye. 9. The method of claim 1 wherein the isolated cell or cell population is grown to about 80% confluence. 10. The method of claim 8 wherein the membrane potential dye is CC2-DMPVE , DiSBAC2(3) or ESS-CY4. 11. The method of claim 1 wherein the expressed delta subunit is encoded by the sequence in SEQ ID NO:7. 12. The method of claim 11 wherein the expressed alpha and beta subunits respectively contain the polypeptides encoded by SEQ ID NO:1 and 2.

Assignees

Inventors

Classifications

  • involving cells · CPC title

  • in screening processes · CPC title

  • for animal cells · CPC title

  • Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title

  • for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics (antimicrobial activity C12Q1/18) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10215759B2 cover?
In one aspect, the present invention relates to a mammalian cell-based high-throughput assay for the profiling and screening of human epithelial sodium channel (hENaC) cloned from a human kidney c-DNA library and is also expressed in other tissues including human taste tissue. The present invention further relates to amphibian oocyte-based medium-throughput electrophysiological assays for ident…
Who is the assignee on this patent?
Senomyx Inc
What technology area does this patent fall under?
Primary CPC classification G01N33/6872. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Feb 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).